Cargando…

Weekly docetaxel in the treatment of metastatic breast cancer

Breast cancer is the most frequent tumor among women worldwide and is the second cause of cancer-related mortality in the US. Metastatic breast cancer (MBC) accounts for less than 10% of newly diagnosed breast cancer patients and about 30% of early breast cancer patients will develop recurrent, adva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palmeri, Laura, Vaglica, Marina, Palmeri, Sergio
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621419/ https://www.ncbi.nlm.nih.gov/pubmed/19209285

Ejemplares similares

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
por: Gamucci, T, et al.
Publicado: (2007)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Remarkable response to pericardial window procedure and weekly docetaxel treatment in a metastatic breast cancer patient with pericardial effusion and cardiac tamponade
por: Ucche, Meita, et al.
Publicado: (2020)

Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer
por: Bacinschi, Xenia Elena, et al.
Publicado: (2020)

Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer
por: Rajappa, Senthil, et al.
Publicado: (2018)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
por: Rescigno, Pasquale, et al.
Publicado: (2018)

Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
por: Pant, Shubham, et al.
Publicado: (2008)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer
por: Li, Fenghu, et al.
Publicado: (2019)

Review of docetaxel in the treatment of gastric cancer
por: Tetzlaff, Eric D, et al.
Publicado: (2008)

Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
por: Engebraaten, Olav, et al.
Publicado: (2012)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Kim, Moon Jin, et al.
Publicado: (2019)

Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer
por: Walker, Leslie G, et al.
Publicado: (2011)

A preliminary study of (18)F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
por: Gong, Chengcheng, et al.
Publicado: (2017)

Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807)
por: Hironaka, Shuichi, et al.
Publicado: (2014)

Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma
por: Minichillo, Santino, et al.
Publicado: (2015)

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial
por: Nuzzo, Francesco, et al.
Publicado: (2011)

Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review
por: Tresnanda, Raden Indra, et al.
Publicado: (2021)

Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma
por: Comella, P, et al.
Publicado: (2003)

Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy
por: Andres, R, et al.
Publicado: (2002)

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
por: Vasey, P A, et al.
Publicado: (2002)

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
por: Ciardiello, F, et al.
Publicado: (2006)

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer
por: Belfiglio, Maurizio, et al.
Publicado: (2011)

Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer
por: Ramagopalan, Sreeram V., et al.
Publicado: (2021)

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
por: Sartor, A Oliver
Publicado: (2011)

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Docetaxel-induced Hand and Foot Syndrome in a Patient with Metastatic Breast Carcinoma
por: Gurumurthi, Ravichandran, et al.
Publicado: (2013)

Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation
por: Varnai, Reka, et al.
Publicado: (2019)

HIV Vif protein in docetaxel treatment of breast cancer cells
por: Cipriano, Pedro, et al.
Publicado: (2021)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
por: Joensuu, H., et al.
Publicado: (2010)

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study
por: Li, Jinyu, et al.
Publicado: (2015)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Benefit risk assessment and update on the use of docetaxel in the management of breast cancer
por: Alken, Scheryll, et al.
Publicado: (2013)

Presentation and management of docetaxel-related adverse effects in patients with breast cancer
por: Ho, Maria Y, et al.
Publicado: (2014)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ck1ul3rthoigc4l9842pd6umm7